In a filing, Dyne Therapeutics Inc revealed its Chief Commercial Officer Friedl-Naderer Johanna unloaded Company’s shares for reported $11863.0 on Sep 04 ’25. In the deal valued at $13.27 per share,894 shares were sold. As a result of this transaction, Friedl-Naderer Johanna now holds 95,017 shares worth roughly $1.26 million.
Then, Friedl-Naderer Johanna sold 144 shares, generating $1,931 in total proceeds. Upon selling the shares at $13.41, the Chief Commercial Officer now owns 94,873 shares.
Before that, Kerr Douglas sold 3,552 shares. Dyne Therapeutics Inc shares valued at $47,135 were divested by the Chief Medical Officer at a price of $13.27 per share. As a result of the transaction, Kerr Douglas now holds 89,263 shares, worth roughly $1.19 million.
Raymond James upgraded its Dyne Therapeutics Inc [DYN] rating to a Strong buy from a an Outperform in a research note published recently. A number of analysts have revised their coverage, including Bernstein’s analysts, who began to cover the stock in late June with a ‘”a Mkt perform”‘ rating.
Price Performance Review of DYN
On Monday, Dyne Therapeutics Inc [NASDAQ:DYN] saw its stock fall -6.47% to $13.3. Over the last five days, the stock has lost -1.41%. Dyne Therapeutics Inc shares have fallen nearly -60.60% since the year began. Nevertheless, the stocks have fallen -43.55% over the past one year. While a 52-week high of $37.08 was reached on 01/02/25, a 52-week low of $6.36 was recorded on 04/09/25.
Levels Of Support And Resistance For DYN Stock
The 24-hour chart illustrates a support level at 12.98, which if violated will result in even more drops to 12.66. On the upside, there is a resistance level at 13.92. A further resistance level may holdings at 14.54.
How much short interest is there in Dyne Therapeutics Inc?
A steep rise in short interest was recorded in Dyne Therapeutics Inc stocks on 2025-08-15, growing by 1.41 million shares to a total of 17.14 million shares. Yahoo Finance data shows the prior-month short interest on 2025-07-15 was 15.73 million shares. There was a rise of 8.23%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on May 29, 2025 when Evercore ISI began covering the stock and recommended ‘”an Outperform”‘ rating along with a $46 price target.
